Additional Study Information: This is a prospective, single-center, single-blind, two-arm, 1:1 randomized clinical trial. Patients who have undergone successful elective PCI will be screened with a lipid profile and eligible patients will be enrolled. Non-eligible patients will be enrolled in a registry. Randomization will be stratified by baseline LDL-C level and current statin therapy. In the intervention arm, LLT will be adjusted prior to discharge based on baseline LDL-C levels and according to a trial-specific algorithm for LLT; subjects and referring physicians will receive an algorithm with suggested LLT goals and therapeutic guidance according to repeat LDL-C levels. Subjects randomized to the control arm will receive standard post-elective PCI care (with follow-up calls as per study protocol). Telehealth monitoring and lipid profile assessment will occur at 2, 4, 6 and 12 months. All subjects will be followed via telephone. Subjects randomized to the intervention arm will receive specific instructions regarding LLT according to repeat LDL-C levels . A note will be sent to the referring physician with recommendations regarding LDL-C and non-HDL-C goals and LLT recommendations.